Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | FABP6 | P51161 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3300228 | 0.82 | TP53 (0.46) | TP53NPSR1SMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL16094970 | 0.80 | POLB (0.42) | TP53SMN1; SMN2TSHRALDH1A1KDM4E | |
| SCHEMBL27845893 | 0.77 | TP53 (0.46) | TP53NPSR1SMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL1773952 | 0.75 | TP53 (0.52) | TP53NPSR1SMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL1299646 | 0.74 | TP53 (0.39) | TP53NPSR1SMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL28780703 | 0.74 | TP53 (0.47) | TP53NPSR1SMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL14761384 | 0.73 | TP53 (0.50) | TP53NPSR1SMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL12634 | 0.73 | KDM4E (0.53) | TP53NPSR1SMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL2769248 | 0.72 | TP53 (0.46) | TP53NPSR1SMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL2769250 | 0.72 | TP53 (0.46) | TP53NPSR1SMN1; SMN2TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11173162-B2 | Bicyclic heterocycles as FGFR4 inhibitors | INCYTE CORPORATION (US) | 2021-11-16 | — | — | US | disclosed |
| EP-3617205-B1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORP (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20200306256-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | INCYTE CORPORATION | 2020-10-01 | — | — | US | disclosed |
| US-10632126-B2 | Bicyclic heterocycles as FGFR4 inhibitors | INCYTE CORPORATION (US) | 2020-04-28 | — | — | US | disclosed |
| EP-3259269-B9 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORP (US) | 2020-03-04 | — | — | EP | disclosed |
| EP-3617205-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | Incyte Corporation (US) | 2020-03-04 | — | — | EP | disclosed |
| US-20190269693-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | INCYTE CORPORATION | 2019-09-05 | — | — | US | disclosed |
| EP-3259269-B1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORP (US) | 2019-09-04 | — | — | EP | disclosed |
| US-10251892-B2 | Bicyclic heterocycles as FGFR4 inhibitors | INCYTE CORPORATION (US) | 2019-04-09 | — | — | US | disclosed |
| EP-3259269-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | Incyte Corporation (US) | 2017-12-27 | — | — | EP | disclosed |
| US-20170290839-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | INCYTE CORPORATION | 2017-10-12 | — | — | US | disclosed |
| US-9708318-B2 | Bicyclic heterocycles as FGFR4 inhibitors | INCYTE CORPORATION (US) | 2017-07-18 | — | — | US | disclosed |
| WO-2016134320-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2016-08-25 | — | — | WO | disclosed |
| US-20160244449-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | INCYTE CORPORATION | 2016-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200306256-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | FGFR4, FGFR3, FGFR1 | TP53 658/4885NPSR1 4061/4885SMN1; SMN2 3304/4885 |
| US-10251892-B2 | Bicyclic heterocycles as FGFR4 inhibitors | FGFR4, FGFR3, FGFR1 | TP53 808/4885NPSR1 3903/4885SMN1; SMN2 2510/4885 |
| US-10632126-B2 | Bicyclic heterocycles as FGFR4 inhibitors | FGFR4, FGFR3, FGFR1 | TP53 808/4885NPSR1 3903/4885SMN1; SMN2 2510/4885 |
| US-20190269693-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | FGFR4, FGFR3, FGFR1 | TP53 808/4885NPSR1 3903/4885SMN1; SMN2 2510/4885 |
| US-20170290839-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | FGFR4, FGFR3, FGFR1 | TP53 658/4885NPSR1 4061/4885SMN1; SMN2 3304/4885 |
| US-11173162-B2 | Bicyclic heterocycles as FGFR4 inhibitors | FGFR4, FGFR3, FGFR1 | TP53 808/4885NPSR1 3903/4885SMN1; SMN2 2510/4885 |
| US-20160244449-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | FGFR4, FGFR3, FGFR1 | TP53 658/4885NPSR1 4061/4885SMN1; SMN2 3304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.